BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20704752)

  • 1. Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain.
    Koizumi M; Yoshimoto M; Kasumi F; Iwase T; Ogata E
    BMC Cancer; 2010 Aug; 10():423. PubMed ID: 20704752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
    Tanaka R; Yonemori K; Hirakawa A; Kinoshita F; Takahashi N; Hashimoto J; Kodaira M; Yamamoto H; Yunokawa M; Shimizu C; Fujimoto M; Fujiwara Y; Tamura K
    Oncologist; 2016 Apr; 21(4):508-13. PubMed ID: 26975863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ; Kaura S
    J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark.
    Jensen AØ; Jacobsen JB; Nørgaard M; Yong M; Fryzek JP; Sørensen HT
    BMC Cancer; 2011 Jan; 11():29. PubMed ID: 21261987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
    Trinkaus M; Simmons C; Myers J; Dranatisaris G; Clemons M
    Support Care Cancer; 2010 Feb; 18(2):197-203. PubMed ID: 19424729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and risk factors of bone metastasis and skeletal related events in patients with primary breast cancer in Japan.
    Yamashiro H; Takada M; Nakatani E; Imai S; Yamauchi A; Tsuyuki S; Matsutani Y; Sakata S; Wada Y; Okamura R; Harada T; Tanaka F; Moriguchi Y; Kato H; Higashide S; Kan N; Yoshibayashi H; Suwa H; Okino T; Nakayama I; Ichinose Y; Yamagami K; Hashimoto T; Inamoto T; Toi M
    Int J Clin Oncol; 2014 Oct; 19(5):852-62. PubMed ID: 24292334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates and other bone agents for breast cancer.
    Wong MH; Stockler MR; Pavlakis N
    Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
    Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
    Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skeletal-related events in advanced lung adenocarcinoma patients evaluated EGFR mutations.
    Nagata M; Kudoh S; Mitsuoka S; Suzumura T; Umekawa K; Tanaka H; Matsuura K; Kimura T; Yoshimura N; Hirata K
    Osaka City Med J; 2013 Jun; 59(1):45-52. PubMed ID: 23909080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate.
    Miyashita H; Cruz C; Malamud S
    Breast Cancer Res Treat; 2020 Jul; 182(2):381-388. PubMed ID: 32474744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
    Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
    Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population.
    Bhowmik D; Song X; Intorcia M; Gray S; Shi N
    Curr Med Res Opin; 2019 Mar; 35(3):513-523. PubMed ID: 30286662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.
    Kremer R; Gagnon B; Meguerditchian AN; Nadeau L; Mayo N
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25278509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.
    Silvestris N; Pantano F; Ibrahim T; Gamucci T; De Vita F; Di Palma T; Pedrazzoli P; Barni S; Bernardo A; Febbraro A; Satolli MA; Bertocchi P; Catalano V; Giommoni E; Comandone A; Maiello E; Riccardi F; Ferrara R; Trogu A; Berardi R; Leo S; Bertolini A; Angelini F; Cinieri S; Russo A; Pisconti S; Brunetti AE; Azzariti A; Santini D
    PLoS One; 2013; 8(10):e74402. PubMed ID: 24204569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opioid Use Among Metastatic Prostate Cancer Patients With Skeletal-related Events.
    Yaldo A; Wen L; Ogbonnaya A; Valderrama A; Kish J; Eaddy M; Kreilick C; Tangirala K; Shields K
    Clin Ther; 2016 Aug; 38(8):1880-9. PubMed ID: 27478111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features and prognosis in 104 colorectal cancer patients with bone metastases].
    Hong RX; Lin QJ; Luo J; Dai Z; Wang WN
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):787-91. PubMed ID: 24378104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
    J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007).
    Yong M; Jensen AÖ; Jacobsen JB; Nørgaard M; Fryzek JP; Sørensen HT
    Breast Cancer Res Treat; 2011 Sep; 129(2):495-503. PubMed ID: 21461730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.